Last A$0.01 AUD
Change Today +0.001 / 10.00%
Volume 2.1M
PAA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 12:10 AM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).

pharmaust ltd (PAA) Snapshot

Open
A$0.01
Previous Close
A$0.01
Day High
A$0.01
Day Low
A$0.01
52 Week High
02/17/14 - A$0.02
52 Week Low
07/16/13 - A$0.0080
Market Cap
15.8M
Average Volume 10 Days
1.5M
EPS TTM
A$-0.0011
Shares Outstanding
1.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMAUST LTD (PAA)

Related News

No related news articles were found.

pharmaust ltd (PAA) Related Businessweek News

No Related Businessweek News Found

pharmaust ltd (PAA) Details

PharmAust Limited, through its subsidiaries, provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries in Australia and internationally. The company operates through Corporate, Exploration, and Pharmaceutical segments. It offers a range of pharmaceutical impurities, degradants, and metabolites of active ingredients and excipients primarily for OTC and generic drugs. The company is also involved in the custom synthesis of analogue libraries, scaffolds, and intermediates; contract drug discovery activities; and development of therapeutic cancer products. In addition, it engages in the exploration of tenements for minerals, and oil and gas. The company holds 80% downstream interests in the Luke River project, a precious and base metal exploration project located in northeast Macedonia. PharmAust Limited is based in Nedlands, Australia.

4 Employees
Last Reported Date: 08/30/13

pharmaust ltd (PAA) Top Compensated Officers

Managing Director of Epichem Pty Ltd
Total Annual Compensation: A$137.0K
Compensation as of Fiscal Year 2013.

pharmaust ltd (PAA) Key Developments

Pharmaust Announce Receives Approval for Clinical Study in Man with PPL-1

PharmAust Limited announced that it has now received approval from the Research Ethics Committee of the Royal Adelaide Hospital to begin evaluation of proprietary drug PPL- 1 in a Phase l/ll clinical trial. The clinical trial will be undertaken by the Royal Adelaide Hospital in approximately 12-15 human patients suffering from a variety of late stage cancers, potentially including the major cancers such as lung, pancreas, oesophageal, gastric, colorectal, ovarian, breast, prostate, liver, sarcoma, lymphoma, and melanoma. In addition to measuring safety and pharmacokinetics of PPL-1, the trial will determine changes in various cancer markers. Furthermore, the patient tumours will be biopsied where possible and also studied with the aid of a CT- PET scanner. Evaluation of PPL-1 is being undertaken in late stage cancer patients under the supervision of Professor Michael Brown (Principal Investigator). All patients recruited in the trial will have failed 'Standard of Care' and will have been without treatment for at least two weeks. The study will look at increasing doses of PPL-1 in cohorts of patients with each dose being administered daily for a period of 28 days. The recruitment of patients by the Royal Adelaide Hospital will begin as soon as Site Specific Assessments have been undertaken and Governance Approval received. The cancer chemotherapy market (estimated at $42 billion/annum) is currently the growing sector within the pharma industry, mainly driven by the identification of new potential therapeutic targets.

PharmAust Limited Announces Application to the Cancer Clinical Trials Unit of the Royal Adelaide Hospital

Pharmaust Limited announced that it has submitted an application to the Cancer Clinical Trials Unit of the Royal Adelaide Hospital to begin evaluation of proprietary drug PPL-1 in a Phase l/ll clinical trial. Subject to consideration and approval by the Investigational Drugs Subcommittee and the Research Ethics Committee, the trial will commence recruiting patients with treatment refractory solid tumours. As a 'First in Man' study, the trial will primarily focus on the safety and pharmacokinetics of the drug, however, the evaluation is being undertaken in late stage cancer patients and as such the clinical team under the supervision of Professor Michael Brown (Principal Investigator) will also have the opportunity to determine the effects of PPL-1 on the cancer itself.

PharmAust Limited Reports Consolidated Earnings Results for the First Half Ended December 31, 2013

PharmAust Limited reported consolidated earnings results for the first half ended December 31, 2013. For the period, the company's revenue was AUD 1,078,245 compared to AUD 972,027 a year ago. Loss before income tax expense was AUD 639,984 compared to AUD 324,139 a year ago. Loss was AUD 639,984 or 0.05 cents per basic and diluted share compared to AUD 324,139 or 0.06 cents per basic and diluted share a year ago. Net cash used in operating activities was AUD 1,272,634 compared to AUD 84,375 a year ago. Payments for plant and equipment were AUD 101,695.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PAA:AU A$0.01 AUD +0.001

PAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PAA.
View Industry Companies
 

Industry Analysis

PAA

Industry Average

Valuation PAA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAUST LTD, please visit www.pharmaust.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.